Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP
January 28, 2016 at 07:37 AM EST
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune ...